Arbutus Biopharma Corp Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Arbutus Biopharma Corp (ABUS) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $37.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-03-23
- Arbutus Biopharma Corp other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $37.00K, a 87.06% decline from fiscal 2024.
- Arbutus Biopharma Corp other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $286.00K, a 86.16% decline from fiscal 2023.
- Arbutus Biopharma Corp other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $2.07M.
- Arbutus Biopharma Corp other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$2.15M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|
| 2025-12-31 | $37.00K 10-K · filed 2026-03-23 |
| 2024-12-31 | $286.00K 10-K · filed 2026-03-23 |
| 2023-12-31 | $2.07M 10-K · filed 2025-03-27 |
| 2022-12-31 | -$2.15M 10-K · filed 2024-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |